About us

Our lead product is our AVERSA technology. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiS use and Accidental exposure of drugs with abuse potential specifically Opioids. Our first application for AVERSA is for our abuse deterrent fentanyl transdermal patch which we are developing to provide clinicians and patients with an extended release chronic pain relief. The goal is to make these pain treatments safe for all who need them. When used correctly they provide incredible relief and care to chronic pain patients.

Nutriband acquired 4P Therapeutics on August 1, 2018.

As a result of the acquisition, the focus of our business changed from the development and marketing of consumer transdermal products to the development of 4P Therapeutics’ portfolio of pharmaceutical transdermal products, with our lead product being the abuse deterrent fentanyl transdermal system.

Our AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with Patent prosecution in the United States and Canada. We have made sure to target all large applicable markets and our Global patent protection has opened up many opportunities for Nutriband to make a big impact on the safety profile of drugs globally.

Nutriband acquired Pocono Pharma on December 1, 2020.